Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL-1002 for Knee Pain Associated With Osteoarthritis
NCT05470608Phase 2Unknown
- Sponsor
- Saol Therapeutics
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA) comparing SL-1002 with Placebo (2 arms). Primary endpoints: Occurrence of treatment emergent adverse events at Day 168 and Improvement of knee pain at Month 3. Status: unknown.
02
Drugs
SL-1002
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05470608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470608.